The Zhitong Finance App learned that British pharmaceutical giant GlaxoSmithKline (GSK.US) said on Wednesday local time that its experimental drug to treat chronic hepatitis B infection has reached major goals in two major clinical studies that have attracted market attention, which will also bring the functional cure of this disease affecting more than 250 million people around the world one step closer. Furthermore, this high-profile new drug may strongly help GlaxoSmithKline achieve its ambitious revenue goals.

The Zhitong Finance App learned that British pharmaceutical giant GlaxoSmithKline (GSK.US) said on Wednesday local time that its experimental drug to treat chronic hepatitis B infection has reached major goals in two major clinical studies that have attracted market attention, which will also bring the functional cure of this disease affecting more than 250 million people around the world one step closer. Furthermore, this high-profile new drug may strongly help GlaxoSmithKline achieve its ambitious revenue goals.